Sandoz Group Ltd SDZ
SIX · Switzerland · Health Technology
CHF 68.42-2.44 (-3.44%)
Market closed· · CHF · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · CHF · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
GRFS vs. SDZNY: Which Stock Is the Better Value Option?
As more psychedelic drugs move toward market, developers are testing how far patent protection can extend around familiar compounds.
Sandoz’s chief commercial officer discusses the company’s ambitious plans to have a biosimilar-driven growth engine by 2040.
Sandoz Group (SWX:SDZ) has moved back into focus after partnering with mAbxience on a proposed emicizumab biosimilar for hemophilia A, adding another rare disease project to its global generics and biosimilars portfolio. Recent announcements around GLP-1 products, fresh bond issuance in Europe and new biosimilar capacity in Slovenia have arrived during a mixed stretch for Sandoz Group, with a 30-day share price return down 7.07% but a 1-year total shareholder return of 44.28% that points to...
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.